Evidence map›Paper›PMID 40520874›Full record

ReviewAmerican journal of cancer research2025

Organoid technology in cervical cancer research.

Hui Ye, Liang Song, Qingli Li, Chongyang Shen, Yuedong He, Lin Li

Abstract readReview
In one paragraph

Review in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hui YeDepartment of Gynecology, West China Second University Hospital, Sichuan University Chengdu 610041, Sichuan, China.
Liang SongDepartment of Tumor Chemoradiotherapy, West China Second University Hospital, Sichuan University Chengdu 610041, Sichuan, China.
Qingli LiDepartment of Tumor Chemoradiotherapy, West China Second University Hospital, Sichuan University Chengdu 610041, Sichuan, China.
Chongyang ShenBasic Medicine School, Chengdu University of Traditional Chinese Medicine Chengdu 611137, Sichuan, China.
Yuedong HeDepartment of Gynecology, West China Second University Hospital, Sichuan University Chengdu 610041, Sichuan, China.
Lin LiDepartment of Gynecology, West China Second University Hospital, Sichuan University Chengdu 610041, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer poses a serious threat to women's lives and health, and it may cause damage to the reproductive system, infertility, and even death. This study reviews the research progress of organoids in the treatment of cervical cancer. Studies have found that the culturing of tumor cell lines and the modeling techniques of tumor xenotransplantation for cervical cancer have certain limitations. Cervical cancer organoids are preclinical research models formed by culturing tumor cells derived from patients, which more accurately and effectively retain tumor heterogeneity, and also have the potential to take into account the interaction between tumor cells and the extracellular matrix. This article reviews the research on cervical cancer organoid models in the pathogenesis, drug screening, and precision medicine aspects in recent years, and then analyzes the development prospects and challenges of organoid technology in gynecological tumor research, in order to explore new possibilities for individualized treatment of cervical cancer.

Indexed as

cervical cancerdrug screening experimentsOrganoidprecision medicinepreclinical model

Identifiers

PMID40520874
PMCPMC12163444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.